Ensysce Biosciences Inc (ENSC)

$7.77 +0.77 (11.00%)
Market Cap 9.14M
Revenue (ttm) 2.23M
Net Income (ttm) -10.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475.78%
Debt to Equity Ratio 0.00
Volume 34,400
Avg Vol 370,891
Day's Range N/A - N/A
Shares Out 1.31M
Stochastic %K 40%
Beta 0.55
Analysts Strong Buy
Price Target $128.94

Latest News on ENSC

Ensysce Biosciences Issues Annual Shareholder Letter

Jan 8, 2025, 8:00 AM EST - 9 days ago

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 23, 2024, 8:00 AM EST - 25 days ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 10, 2024, 8:00 AM EST - 5 weeks ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 4, 2024, 8:00 AM EST - 6 weeks ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Dec 3, 2024, 4:15 PM EST - 6 weeks ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 26, 2024, 8:00 AM EST - 7 weeks ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:15 PM EST - 2 months ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Nov 7, 2024, 8:00 AM EST - 2 months ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 8, 2024, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Oct 2, 2024, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Ensysce Biosciences Receives Notice from Nasdaq

Sep 27, 2024, 4:30 PM EDT - 4 months ago

Ensysce Biosciences Receives Notice from Nasdaq

Ensysce Biosciences Presenting at Upcoming Meetings

Sep 24, 2024, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Presenting at Upcoming Meetings

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Sep 19, 2024, 7:00 AM EDT - 4 months ago

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Sep 13, 2024, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Aug 29, 2024, 8:00 AM EDT - 5 months ago

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Aug 27, 2024, 2:30 PM EDT - 5 months ago

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Aug 27, 2024, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Aug 23, 2024, 8:00 AM EDT - 5 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:15 PM EDT - 5 months ago

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Aug 8, 2024, 8:25 AM EDT - 5 months ago

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Ensysce Biosciences Provides Mid-Year 2024 Update

Jul 23, 2024, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Provides Mid-Year 2024 Update

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Jul 9, 2024, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

Jun 27, 2024, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

Jun 25, 2024, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

Jun 6, 2024, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

Jun 3, 2024, 8:00 AM EDT - 8 months ago

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 20, 2024, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

Ensysce Biosciences Reports First Quarter 2024 Financial Results

May 13, 2024, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Reports First Quarter 2024 Financial Results

Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

Apr 25, 2024, 8:00 AM EDT - 9 months ago

Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

Apr 19, 2024, 8:00 AM EDT - 9 months ago

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 9, 2024, 8:00 AM EDT - 10 months ago

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 15, 2024, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

Feb 21, 2024, 8:00 AM EST - 11 months ago

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Feb 15, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Feb 13, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

Jan 31, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

Jan 25, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

Jan 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

Ensysce Biosciences Issues 2024 Shareholder Letter

Jan 8, 2024, 8:15 AM EST - 1 year ago

Ensysce Biosciences Issues 2024 Shareholder Letter

Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

Dec 19, 2023, 4:15 PM EST - 1 year ago

Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic

Dec 14, 2023, 8:15 AM EST - 1 year ago

Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic

Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast

Dec 11, 2023, 9:00 AM EST - 1 year ago

Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast

Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing

Nov 29, 2023, 8:05 AM EST - 1 year ago

Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing

Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States

Nov 28, 2023, 8:15 AM EST - 1 year ago

Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

Nov 16, 2023, 8:15 AM EST - 1 year ago

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

Ensysce Biosciences Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:30 PM EST - 1 year ago

Ensysce Biosciences Reports Third Quarter 2023 Financial Results

Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

Oct 24, 2023, 8:15 AM EDT - 1 year ago

Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360

Oct 18, 2023, 8:15 AM EDT - 1 year ago

Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360

Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium

Oct 13, 2023, 8:15 AM EDT - 1 year ago

Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium